World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management

American Journal of Hematology

Volumn 90, Issue 11, 2015, Pages 1077-1089

  Gotlib, Jason ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CORTICOSTEROID; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; INTERLEUKIN 3; INTERLEUKIN 5; MEPOLIZUMAB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STEROID; ANTINEOPLASTIC AGENT; FGFR1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ACUTE MYELOBLASTIC LEUKEMIA; CHRONIC EOSINOPHILIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CLONAL VARIATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOGENETICS; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EOSINOPHIL COUNT; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; LUNG FUNCTION; LYMPHOCYTE VARIANT HYPEREOSINOPHILIA; LYMPHOPROLIFERATIVE DISEASE; NOTE; PALLIATIVE THERAPY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REMISSION; SEROLOGY; T LYMPHOCYTE; TREATMENT DURATION; WORLD HEALTH ORGANIZATION; CLASSIFICATION; DISEASE MANAGEMENT; DRUG EFFECTS; EOSINOPHIL; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; MUTATION; PATHOLOGY; RISK ASSESSMENT;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; EOSINOPHILIA; EOSINOPHILS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; MUTATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RISK ASSESSMENT;

EID: 84944625994     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24196     Document Type: Note

References (163)

1. Crane MM, Chang CM, Kobayashi MG, et al. Incidence of myeloproliferative hypereosinophilic syndrome in the Unites States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 2010; 126:179-181.
2. Gotlib J, Cools J. Five years since the discovery of the FIPL1-PDGFRA: What we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008; 22:1999-2010.
3. Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007; 109:4635-4640.
4. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104:3038-3045.
5. Pardanani A, Ketterling RP, Li CY, et al. FIP1L1-PDGFRA in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006; 30:965-970.
6. Wynn SR, Sachs MI, Keating MU, et al. Idiopathic hypereosinophilic syndrome in a 5 1/2-month-old infant. J Pediatr 1987; 111:94-97.
7. Bakhshi S, Hamre M, Mohamed AM, et al. t(5;9)(q11;q34): A novel familial translocation involving Abelson oncogene and association with hypereosinophilia. J Pediatr Hematol Oncol 2003; 25:82-84.
8. Rives S, Alcorta I, Toll T, et al. Idiopathic hypereosinophilic syndrome in children: Report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement. J Pediatr Hematol Oncol 2005; 27:663-665.
9. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348:1201-1214.
10. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92:1173-1179.
11. Brigden M, Graydon C. Eosinophilia detected by automated blood cell counting in ambulatory North American outpatients. Incidence and clinical significance. Arch Pathol Lab Med 1997; 121:963-967.
12. Rothenberg ME. Eosinophilia. New Engl J Med 1998; 338:1592-1600.
13. Pardanani A, Patnaik MM, Tefferi A. Eosinophilia: Secondary, clonal and idiopathic. Br J Haematol 2006; 133:468-492.
14. Bain BJ, Gilliland DG, Horny H-P, et al. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. In: Swerdlow S, Harris NL, Stein H, Jaffe ES, Theile J, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2008. pp 68-73.
15. Bain BJ, Gilliland DG, Horny H-P, et al. Chronic eosinophilic leukaemia, not otherwise specified. In: Swerdlow S, Harris NL, Stein H, Jaffe ES, Theile J, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press. 2008. pp 51-53.
16. Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome. Analysis of fourteen cases with review of the literature. Medicine 1975; 54:1-27.
17. Valent P, Klion D, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012; 130:607-612.e9.
18. Fauci AS, Harley JB, Roberts WC, et al. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982; 97:78-92.
19. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndromes: A multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124:1319-1325.
20. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83:2759-2779.
21. Spry CJ, Davies J, Tai PC, et al. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 1983; 52:1-22.
22. Lefebvre C, Bletry O, Degoulet P, et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases. Ann Med Interne (Paris) 1989; 140:253-257.
23. Flaum MA, Schooley RT, Fauci AS, et al. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. Blood 1981; 58:1012-1020.
24. Gotlib J, Cools J, Malone JM, et al. The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management. Blood 2004; 103:2879-2891.
25. Tanino M, Kitamura K, Ohta G, et al. Hypereosinophilic syndrome with extensive myocardial involvement and mitral valve thrombus instead of mural thrombi. Acta Pathol Jpn 1983; 33:1233-1242.
26. Radford DJ, Garlick RB, Pohlner PG. Multiple valvar replacement for hypereosinophilic syndrome. Cardiol Young 2002; 12:67-70.
27. Ommen SR, Seward JB, Tajik AJ. Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol 2000; 86:110-113.
28. Ganeva M, Gancheva T, Lazarova R, et al. Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: Report of four cases and brief review. Int J Dermatol 2008; 47:853-860.
29. Campos LE, Pereira LF. Pulmonary eosinophilia. J Bras Pneumol 2009; 35:561-573.
30. Mendez-Sanchez N, Chavez-Tapia NC, Vazquez-Elizondo G, et al. Eosinophilic gastroenteritis: A review. Dig Dis Sci 2007; 52:2904-2911.
31. Kawasaki A, Mizushima Y, Matsui S, et al. A case of T-cell lymphoma accompanying marked eosinophilia, chronic eosinophilic pneumonia and eosinophilic pleural effusion. A case report. Tumori 1991; 77:527-530.
32. Endo M, Usuki K, Kitazume K, et al. Hypereosinophilic syndrome in Hodgkin's disease with increased granulocyte-macrophage colony-stimulating factor. Ann Hematol 1995; 71:313-314.
33. Catovksy D, Bernasconi C, Verdonck PJ, et al. The association of eosinophilia with lymphoblastic leukaemia or lymphoma: A study of seven patients. Br J Haematol 1980; 45:523-534.
34. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102:3093-3096.
35. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101:4660-4666.
36. Metzgeroth G, Walz C, Score J, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007; 21:1183-1188.
37. Elling C, Erben P, Walz C, et al. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 2011; 117:2935-2943.
38. Greipp PT, Dewald GW, Tefferi A. Prevalence, breakpoint distribution, and clinical correlates of t(5;12). Cancer Genet Cytogenet 2004; 153:1701186
39. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 1998; 18:84-87.
40. Reiter A, Sohal J, Kulkarni S, et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 1999; 92:1735-1742.
41. Popovici C, Adelaide J, Ollendorff V, et al. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proc Natl Acad Sci USA 1998; 95:5712-5717.
42. Smedley D, Hamoudi R, Clark J, et al. The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. Hum Mol Genet 727:637-642.
43. Simon HU, Plotz SG, Dummer R, et al. Abnormal clones of T cells producing interleukin-5 in idiopathic hypereosinophilia. N Eng J Med 1999; 341:1112-1120.
44. Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004; 59:673-689.
45. Schwaab J, Umbach R, Metzgeroth G, et al. KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance. Am J Hematol. 2015; 90:774-777.
46. Cogan E, Schandene L, Crusiaux A, et al. Brief report: Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994; 330219:538.
47. Simon HU, Yousefi S, Dommann-Scherrer CC, et al. Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med 1996; 183:1071-1082.
48. Brugnoni D, Airo P, Rossi G, et al. CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood 1996; 87:1416-1422.
49. Lefevre G, Copin MC, Staumont-Salle D, et al. The lymphoid variant of hypereosinophilic syndrome: Study of 21 patients with CD3-CD4+ aberrant T-cell phenotype. Medicine (Baltimore). 2014; 93:255-266.
50. Roufosse F, Schandene L, Sibille C, et al. T-cell receptor-independent activation of clonal Th2 cells associated with chronic hypereosinophilia. Blood 1999; 94:994-1002.
51. Bank I, Amariglio N, Reshef A, et al. The hypereosinophilic syndrome associated with CD4+CD3- helper type 2 (Th2) lymphocytes. Leuk Lymphoma 2001; 42:123-133.
52. Klion AD, Mejia R, Cowen EW, et al. Chronic active Epstein-Barr virus infection: A novel cause of lymphocytic variant hypereosinophilic syndrome. Blood 2013; 121:2364-2366.
53. Roufosse F. Hypereosinophilic syndrome variants: Diagnostic and therapeutic considerations. Haematologica 2009; 94:1188-1193.
54. Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J, et al. T-cell abnormalities are present at high frequencies at high frequencies in patients with hypereosinophilic syndrome. Haematologica 2009; 94:1236-1241.
55. DeLavareille A, Roufosse F, Schmid-Grendelmeier P, et al. High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. J Allergy Clin Immunol 2002; 110:476-479.
56. Podjasek JC, Butterfield JH. Mortality in hypereosinophilic syndrome: 19 Years of experience at Mayo Clinic with a review of the literature. Leuk Res 2013; 37:392-395.
57. Helbig G, Soja A, Bartkowska-Chrobok A, et al. Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. Am J Hematol 2012; 87:643-645.
58. Brugnoni D, Airo P, Tosoni C, et al. CD3-CD4+ cells with a Th2-like pattern of cytokine production in the peripheral blood of a patient with cutaneous T cell lymphoma. Leukemia 1997; 11:1983-1985.
59. Roufosse F, Schandene L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 2000; 109:540-548.
60. Kitano K, Ichikawa N, Shimodaira S, et al. Eosinophilia associated with clonal T-cell proliferation. Leuk Lymphoma 1997; 27:335-342.
61. Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009; 114:3769-3772.
62. Wimazal F, Germing U, Kundi M, et al. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes. Cancer 2010; 116:2372-2381.
63. Matsushima T, Handa H, Yokohama A, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 2003; 101:3386-3390.
64. Ackerman SJ, Butterfield JH. Eosinophilia, eosinophil-associated diseases, chronic eosinophilic leukemia, and the hypereosinophilic syndromes. In Hematology, 4th Ed. Hoffman R, Benz Jr. E, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, editors. Churchill Livingstone, Philadelphia, 2005.
65. Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 2003; 121:203-223.
66. Schaller JL, Burkland GA. Case report: Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 2001;3:9.
67. Gleich GJ, Leiferman KM, Pardanani A, et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359:1577-1578.
68. Ault P, Cortes J, Koller C, et al. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 2002; 26:881-884.
69. Griffin JH, Leung J, Bruner RJ, et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 2003; 100:7830-7835.
70. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103:473-478.
71. Helbig G, Stella-Hołowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol 2008; 141:200-204.
72. Legrand F, Renneville A, Macintyre E, et al. The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: New insights based on a survey of 44 cases. Medicine (Baltimore). 2013 Aug 26. [Epub ahead of print]
73. Pardanani A, D'Souza A, Knudson RA, et al. Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: Survival and clinical outcome. Leukemia 2012; 26:2439-2441.
74. Klion AD, Robyn J, Maric I, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: Implications for optimal dosing. Blood 2007; 110:3552-3556.
75. Helbig G, Kyrcz-Krzemień S. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome. Am J Hematol 2014; 89:115
76. Von Bubnoff N, Sandherr M, Schlimok G, et al. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFRalpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2004; 19:286-287.
77. Ohnishi H, Kandabashi K, Maeda Y, et al. Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy. Br J Haematol 2006; 134:547-549.
78. Lierman E, Michaux L, Beullens E, et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009; 23:845-851.
79. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations. Blood 2006; 108:2332-2338.
80. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 2003; 3:459-469.
81. Lierman E, Folens C, Stover EH, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006; 108:1374-1376.
82. Stover EH, Chen J, Lee BH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 2005; 106:3206-3213.
83. von Bubnoff N, Gorantla SP, Thone S, et al. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 2006; 107:4970-4971.
84. Metzgeroth G, Erben P, Martin H, et al. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 2012; 26:162-164.
85. Simon D, Salemi S, Yousefi S, et al. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. J Allergy Clin Immunol 2008; 121:1054-1056.
86. Gorantla SP, Zirlik K, Reiter A, et al. F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA stability via SHP-2 and SRC: A novel mode of kinase inhibitor resistance. Leukemia 2015; 29:1763-1770.
87. Cross DM, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007; 109:61-64.
88. Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014; 123:3574-3577.
89. Chen J, DeAngelo DJ, Kutok JL, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A 2004; 101:14479-14484.
90. Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005; 65:2662-2667.
91. Vu HA, Xinh PT, Masuda M, et al. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia 2006; 20:1414-1421.
92. Lierman E, Selleslag D, Smits S, et al. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2- positive chronic eosinophilic leukemia. Blood 2012; 120:1529-1531.
93. Rumi E, Milosevic JD, Casetti I, et al. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol 2013; 31:e269-e271.
94. Chase A, Bryant C, Score J, Cross NC. Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica 2013; 98:103-106.
95. Ren M, Qin H, Ren R, Cowell JK. Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. Leukemia 2013; 27:32-40.
96. Khodadoust MS, Luo B, Medeiros BC, et al. Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed phenotype acute leukemia. Leukemia, in press.
97. Pardanani A, Reeder T, Porrata L, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101:3391-3397.
98. Pitini V, Arrigo C, Azzarello D, et al. Serum concentration of cardiac troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003; 102:3456-3457.
99. Helbig G, Wiśniewska-Piaty K, Francuz T, et al. Diversity of clinical manifestations and response to corticosteroids for idiopathic hypereosinophilic syndrome: Retrospective study in 33 patients. Leuk Lymphoma 2013; 54:807-811.
100. Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978; 89:167-172.
101. Quiquandon I, Claisse JF, Capiod JC, et al. Alpha-interferon and hypereosinophilic syndrome with trisomy 8: Karyotypic remission. Blood 1995; 85:2284-2285.
102. Luciano L, Catalano L, Sarrantonio C, et al. αIFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5). Haematologica 1999; 84:651-653.
103. Yamada O, Kitahara K, Imamura K, et al. Clinical and cytogenetic remission induced by interferon-α in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Hematol 1998; 58:137-141.
104. Malbrain ML, Van den Bergh H, Zachee P. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: Complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br J Haematol 1996; 92:176-183.
105. Butterfield JH, Gleich GJ. Response of six patients with idiopathic hypereosinophilic syndrome to interferon alpha. J Allergy Clin Immunol 1994; 94:1318-1326.
106. Ceretelli S, Capochiani E, Petrini M. Interferon-alpha in the idiopathic hypereosinophilic syndrome: Consideration of five cases. Ann Hematol 1998; 77:161-164.
107. Yoon TY, Ahn GB, Chang SH. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: Report of a case and literature review. J Dermatol 2000; 27:110-115.
108. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 2005; 114:26-40.
109. Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-a-2b therapy in BCR-ABL-negative myeloproliferative disorders. Final result of a phase 2 study. Cancer 2007; 110:2012-2018.
110. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alpha-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112:3065-3072.
111. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon-alpha-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27:5418-5424.
112. Chusid MJ, Dale DC. Eosinophilic leukemia. Remission with vincristine and hydroxyurea. Am J Med 1975; 59:297-300.
113. Cofrancesco E, Cortellaro M, Pogliani E, et al. Response to vincristine treatment in a case of idiopathic hypereosinophilic syndrome with multiple clinical manifestations. Acta Haematol 1984; 72:21-25.
114. Sakamoto K, Erdreich-Epstein A, deClerck Y, et al. Prolonged clinical response to vincristine treatment in two patients with hypereosinophilic syndrome. Am J Pediatr Hematol Oncol 1992; 14:348-351.
115. Lee JH, Lee JW, Jang CS, et al. Successful cyclophosphamide therapy in recurrent eosinophilic colitis associated with hypereosinophilic syndrome. Yonsei Med J 2002; 43:267-270.
116. Smit AJ, van Essen LH, de Vries EG. Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. Cancer 1991; 67:2826-2827.
117. Bourrat E, Lebbe C, Calvo F. Etoposide for treating the hypereosinophilic syndrome. Ann Intern Med 1994; 121:899-900.
118. Ueno NT, Zhao S, Robertson LE, et al. 2-chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome. Leukemia 1997; 11:1386-1390.
119. Jabbour E, Verstovsek S, Giles F, et al. 2-chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 2005; 104:541-546.
120. Zabel P, Schlaak M. Cyclosporin for hypereosinophilic syndrome. Ann Hematol 1991; 62:230-231.
121. Nadarajah S, Krafchik B, Roifman C, et al. Treatment of hypereosinophilic syndrome in a child using cyclosporine: Implication for a primary T-cell abnormality. Pediatrics 1997; 99:630-633.
122. Butterfield JH. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome. Leuk Res 2009; 33:1127-1129.
123. Helbig G, Hus M. Halasz, et al. Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome. Med Onc 2011; 29:1073-1076.
124. Iurlo A, Gianelli U, Beghini A, et al. Identification of kit (M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. Oncotarget. 2014; 5:4665-4670.
125. Hart TK, Cook RM, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001; 108:250-257.
126. Plotz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003; 349:2334-2339.
127. Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndrome. J Allergy Clin Immunol 2004; 113:115-119.
128. Klion AD, Law MA, Noel P, et al. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004; 103:2939-2941.
129. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. New Engl J Med 2008; 358:1215-1228.
130. Roufosse FE, Kahn JE, Gleich GJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol 2013; 131:461-467.
131. Walsh GM. Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther 2009; 11:329-336.
132. Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012 Feb;129:456-463, 463.e1-3
133. Yamada Y, Rothenberg ME, Lee AW, et al. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 2006; 107:4071-4079.
134. Pitini V, Teti D, Arrigo C, Righi M, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T-cells: A case report. Br J Haematol 2004; 127:477
135. Sefcick A, Sowter D, DasGupta E, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol 2004; 124:558-559.
136. Verstovsek S, Tefferi A, Kantarjian H, et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 2009; 15:368-373.
137. Strati P, Cortes J, Faderl S, et al. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk 2013; 13:287-291.
138. Vazquez L, Caballero D, Canizo CD, et al. Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis. Bone Marrow Transplant 2000;25:217-218.130.
139. Chockalingam A, Jalil A, Shadduck RK, et al. Allogeneic peripheral blood stem cell transplantation for hypereosinophilic syndrome with severe cardiac dysfunction. Bone Marrow Transplant 1999;23:1093-1094.
140. Basara N, Markova J, Schmetzer B, et al. Chronic eosinophilic leukemia: Successful treatment with an unrelated bone marrow transplantation. Leuk Lymphoma 1998; 32:189-193.
141. Sigmund DA, Flessa HC. Hypereosinophilic syndrome: Successful allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15:647-648.
142. Esteva-Lorenzo FJ, Meehan KR, Spitzer TR, et al. Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome. Am J Hematol 1996; 51:164-165.
143. Sadoun A, Lacotte L, Delwail V, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis. Bone Marrow Transplant 1997; 19:741-743.
144. Juvonen E, Volin L, Kopenen A, et al. Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome. Bone Marrow Transplant 2002; 29:457-458.
145. Ueno NT, Anagnostopoulos A, Rondon G, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 2002; 119:131-134.
146. Halaburda K, Prejzner W, Szatkowski D, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome: Long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript. Bone Marrow Transplant 2006; 38:319-320.
147. Blacklock HA, Cleland JF, Tan P, et al. The hypereosinophilic syndrome and leukapheresis. Ann Intern Med 1979; 91:650-651.
148. Davies J, Spry C. Plasma exchange or leukapheresis in the hypereosinophilic syndrome. Ann Intern Med 1982; 96:791
149. Chambers LA, Leonard SS, Whatmough AE, et al. Management of hypereosinophilic syndrome with chronic plasma- and leukapheresis. Prog Clin Biol Res 1990; 337:83-85.
150. Narayan S, Ezughah F, Standen GR, et al. Idiopathic hypereosinophilic syndrome associated with cutaneous infarction and deep venous thrombosis. Br J Dermatol 1993; 148:817-820.
151. Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med 1985; 102:109-114.
152. Johnston AM, Woodcock BE. Acute aortic thrombosis despite anticoagulant therapy in idiopathic hypereosinophilic syndrome. J R Soc Med 1998; 91:492-493.
153. Harley JB, McIntosh XL, Kirklin JJ, et al. Atrioventricular valve replacement in the idiopathic hypereosinophilic syndrome. Am J Med. 1982; 73:77-81.
154. Hendren WG, Jones EL, Smith MD. Aortic and mitral valve replacement in idiopathic hypereosinophilic syndrome. Ann Thorac Surg. 1988; 46:570-571.
155. Cameron J, Radford DJ, Howell J, et al. Hypereosinophilic heart disease. Med J Aust 1985; 143:408-410.
156. Kiris I, Okutan H, Peker T, et al. Mitral valve replacement in a patient with idiopathic hypereosinophilic syndrome and pulmonary artery hypertension. J Card Surg 2009; 24:80-82.
157. Chandra M, Pettigrew RI, Eley JW, et al. Cine-MRI-aided endomyocardectomy in idiopathic hypereosinophilic syndrome. Ann Thorac Surg 1996; 62:1856-1858.
158. Jones AV, Kreil S, Zoi K. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106:2162-2168.
159. Helbig G, Stella-Holowiecka B, Majewski M, et al. Interferon alpha induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation. Haematologica 2007; 92:e118-119.
160. Simon HU, Yousefi S, Dibbert B, et al. Anti-apoptotic signals of granulocyte-macrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils. Eur J Immunol 1997; 27:3536-3539.
161. Miike S, Nakao A, Hiraguri M, et al. Involvement of JAK2, but not PI 3-kinase/AKT and MAP kinase pathways, in anti-apoptotic signals of GM-CSF of human eosinophils. J Leukoc Biol 1999; 65:700-706.
162. Li B, Zhang G, Li C, et al. Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL. PLoS One 2012; 7:e34912
163. Montano-Almendras CP, Essaghir A, et al. ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor proliferation and differentiation into eosinophils: Role of NF-κB. Haematologica 2012; 97:1064-1072.